ストックスクリーナーアプリを入手
29.51
1.63%
-0.49
アフターアワーズ：
29.51
前日終値:
$30.00
開ける：
$29.99
24時間の取引高:
439.00K
Relative Volume:
0.80
時価総額：
$1.37B
収益：
-
当期純損益:
$-166.31M
株価収益率:
-6.6163
EPS:
-4.4602
ネットキャッシュフロー:
$-160.59M
1週間 パフォーマンス:
-4.31%
1か月 パフォーマンス:
-9.31%
6か月 パフォーマンス:
+31.39%
1年 パフォーマンス:
+58.49%
1日の値動き範囲:
$29.13
$30.07
1週間の範囲:
$29.13
$31.60
52週間の値動き範囲:
$17.00
$35.83
Arrivent Biopharma Inc Stock (AVBP) Company Profile
Compare AVBP vs VRTX, REGN, ARGX, RVMD, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
AVBP
Arrivent Biopharma Inc
|
29.51 | 1.47B | 0 | -166.31M | -160.59M | -4.4602 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Arrivent Biopharma Inc Stock (AVBP) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-12 | 再開されました | BTIG Research | Buy |
| 2025-12-10 | 開始されました | BTIG Research | Buy |
| 2025-11-25 | 開始されました | Truist | Buy |
| 2025-07-10 | 再開されました | Goldman | Buy |
| 2025-03-20 | 開始されました | B. Riley Securities | Buy |
| 2025-03-10 | 開始されました | Guggenheim | Buy |
| 2024-07-22 | 開始されました | Oppenheimer | Outperform |
| 2024-04-30 | 開始されました | H.C. Wainwright | Buy |
| 2024-02-20 | 開始されました | Citigroup | Buy |
| 2024-02-20 | 開始されました | Goldman | Buy |
| 2024-02-20 | 開始されました | Jefferies | Buy |
すべてを表示
Arrivent Biopharma Inc (AVBP) 最新ニュース
Technical Reactions to AVBP Trends in Macro Strategies - Stock Traders Daily
A Quick Look at Today's Ratings for ArriVent BioPharma(AVBP.US), With a Forecast Between $40 to $50 - moomoo.com
ArriVent BioPharma (NASDAQ:AVBP) Receives "Buy" Rating from Guggenheim - marketbeat.com
ArriVent BioPharma (NASDAQ:AVBP) Shares Down 4.7% Following Weak Earnings - marketbeat.com
ArriVent BioPharma: Pipeline Progress and Funding Strength Support Buy Rating and Unchanged $42 Price Target - TipRanks
ArriVent BioPharma's (AVBP) "Buy" Rating Reaffirmed at BTIG Research - marketbeat.com
Tema ETFs LLC Invests $1.98 Million in ArriVent BioPharma, Inc. $AVBP - marketbeat.com
Dimensional Fund Advisors LP Has $2.92 Million Stock Holdings in ArriVent BioPharma, Inc. $AVBP - marketbeat.com
AVBP SWOT Analysis: Financial Strength and Growth Potential Reve - GuruFocus
ArriVent BioPharma, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
ArriVent BioPharma (NASDAQ:AVBP) Posts Earnings Results, Misses Expectations By $0.07 EPS - marketbeat.com
ArriVent inks China partnership for ARR-002 development - TipRanks
AVBP: Firmonertinib and novel ADCs show strong clinical progress, with major milestones ahead in 2026 - TradingView
ArriVent BioPharma (NASDAQ: AVBP) details $93M loss and $373M cash buffer - Stock Titan
ArriVent BioPharma reports $49.9 million Q2 net loss - Quiver Quantitative
ArriVent BioPharma Reports Second Quarter 2026 Financial Results - The Manila Times
ArriVent Expects Firmonertinib Lung Cancer Trial Data in 2H 2026 - Stock Titan
ArriVent BioPharma (AVBP) Expected to Release Quarterly Earnings on Friday - marketbeat.com
Trading the Move, Not the Narrative: (AVBP) Edition - Stock Traders Daily
Seven Fleet Capital Management LP Buys New Shares in ArriVent BioPharma, Inc. $AVBP - marketbeat.com
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Vivo Capital LLC Takes $20.44 Million Position in ArriVent BioPharma, Inc. $AVBP - marketbeat.com
141,814 Shares in ArriVent BioPharma, Inc. $AVBP Bought by ADAR1 Capital Management LLC - marketbeat.com
Arrivent Biopharma Inc (AVBP) Cash Flow - TradingKey
Arrivent Biopharma Inc (AVBP) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Arrivent Biopharma Inc (AVBP) Valuation: PE, PB & Fair Value Analysis - TradingKey
Arrivent Biopharma Inc (AVBP) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Arrivent Biopharma Inc (AVBP) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Arrivent Biopharma Inc (AVBP) Institutional Confidence - TradingKey
AVBP|Arrivent Biopharma Inc|Price:30.140|Chg%:-1.590 - TradingKey
Arrivent Biopharma Inc (AVBP) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Arrivent Biopharma Inc (AVBP) Balance Sheet - TradingKey
AVBP|Arrivent Biopharma Inc|Price:31.730|Chg%:+0.190 - TradingKey
ArriVent BioPharma, Inc. Revenue Breakdown – NASDAQ:AVBP - TradingView
Arrivent Biopharma Inc (AVBP) Income Statement - TradingKey
AVBP|Arrivent Biopharma Inc|Price:32.020|Chg%:+0.480 - TradingKey
(AVBP) Volatility Zones as Tactical Triggers - Stock Traders Daily
ArriVent BioPharma (AVBP) Edges Lower, Holding Above Key Support as Consolidation ContinuesLarge Cap Trends - dars.gov.et
ArriVent BioPharma (AVBP) Edges Lower, Testing Support Amid Biotech VolatilityDefined Outcome ETF - dars.gov.et
ArriVent BioPharma Q1 2026 Earnings: EPS Miss Reflects Increased R&D Spending; Shares Edge HigherCEO Earnings Statement - dars.gov.et
LifeSci Capital Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Maintains Target Price $42 - Moomoo
BTIG Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Maintains Target Price $42 - Moomoo
ArriVent’s Firmonertinib Seen as Differentiated EGFR Inhibitor Ahead of FURVENT Readout; Buy Rating Reiterated with Unchanged $42 Price Target - TipRanks
AVBP Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
AVBP Q1 2026 Earnings: EPS Miss Highlights Development Stage ChallengesEPS Growth Rate - DonanımHaber
ArriVent BioPharma (AVBP) Holds Near Support After Modest PullbackFear Greed Index - dars.gov.et
ArriVent BioPharma (AVBP) Edges Lower Amid Consolidation Near Key LevelsPCR Divergence - dars.gov.et
JonesTrading Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Maintains Target Price $45 - Moomoo
ArriVent’s Emerging CDH17-Targeted ADC Pipeline Supports Maintained Buy Rating and $45 Price Target - TipRanks
ArriVent BioPharma, Inc. Financial Disclosures & SEC Filings - TradingView
Price-Driven Insight from (AVBP) for Rule-Based Strategy - Stock Traders Daily
Arrivent Biopharma Inc (AVBP) 財務データ
収益
当期純利益
現金流量
EPS
0.52%
0.07%
大文字化:
|
ボリューム (24 時間):